TABLE 2.
Overview of antibody reactivities of individual epitopes and combinations of HCMV peptide epitopes by ELISAa
| Protein (gene) | Amino acid positions | No.
of serum samples positive/total no. tested (%)
|
|
|---|---|---|---|
| IgG | IgM | ||
| pp150 (UL32) | 595–614 | 16/49 (33) | NT |
| 615–636 | 19/49 (39) | NT | |
| 595–636 | 26/49 (53) | 5/9 (55) | |
| 1011–1048 | 50/57 (88) | 6/9 (67) | |
| pp52 (UL44) | 266–293 | 15/49 (31) | 8/9 (89) |
| 295–312 | 0/49 (0) | 9/9 (100) | |
| gB (UL55) | 792–809 | 0/49 (0) | 4/9 (45) |
| 60–81 | 30/49 (61) | 3/9 (34) | |
| pp28 (UL99) | 15–45 | 24/49 (84) | 4/9 (45) |
| 130–160 | 41/49 (84) | 0/9 (0) | |
| Combination IgG | 188/190 (98.9) | NT | |
| Combination IgM | NT | 80/83 (96.4) | |
a
Sera from HCMV-seropositive blood donors were tested for peptides with IgG reactivity. Nine serum samples from nine transplant recipients obtained after seroconversion were tested for IgM reactivity. Positivity was an OD450 value greater than three times the standard deviation of the mean for a panel of five HCMV-negative serum samples. NT, not tested.